Scilex Holding Co (Scilex Holding Co) Cash-to-Debt : 0.02 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Scilex Holding Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Scilex Holding Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.02.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Scilex Holding Co couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Scilex Holding Co's Cash-to-Debt or its related term are showing as below:

SCLX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.03 Max: 1.55
Current: 0.02

During the past 5 years, Scilex Holding Co's highest Cash to Debt Ratio was 1.55. The lowest was 0.02. And the median was 0.03.

SCLX's Cash-to-Debt is ranked worse than
95.42% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs SCLX: 0.02

Scilex Holding Co Cash-to-Debt Historical Data

The historical data trend for Scilex Holding Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Scilex Holding Co Cash-to-Debt Chart

Scilex Holding Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

N/A

0.04

0.03

1.55

0.03

Scilex Holding Co Quarterly Data
	Dec19	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial							0.47	0.90	0.02	0.03	0.02

Competitive Comparison of Scilex Holding Co's Cash-to-Debt

For the Drug Manufacturers - General subindustry, Scilex Holding Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scilex Holding Co's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Scilex Holding Co's Cash-to-Debt falls into.

Scilex Holding Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Scilex Holding Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.921	/	(109.188	+	19.275)
	=	0.03

Scilex Holding Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.818	/	(93.654	+	18.391)
	=	0.02

Scilex Holding Co (NAS:SCLX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Scilex Holding Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Scilex Holding Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Scilex Holding Co (Scilex Holding Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scilex Holding Co (NAS:SCLX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

960 San Antonio Road, Palo Alto, CA, USA, 94303

Website

https://www.scilexholding.com

Scilex Holding Co is engaged in the development and commercialization of non-opioid pain management products. The company's lead product ZTlido.

Executives

Sclx Stock Acquisition Jv Llc	10 percent owner	960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Jay Chun	director	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Yue Alexander Wu	director	C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
Stephen Hoi Ma	officer: Chief Financial Officer	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105
Tien-li Lee	director	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Sorrento Therapeutics, Inc.	10 percent owner	4955 DIRECTORS PLACE, SAN DIEGO CA 92121
David Lemus	director	C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Dorman Followwill	director	C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Henry Ji	director, officer: Executive Chairperson	5370 RUETTE DE MER, SAN DIEGO CA 92130
Jaisim Shah	director, officer: See Remarks	C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560
Elizabeth Czerepak	officer: See Remarks	201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Suneel G Kaji	director	25/28 OLD BURLINGTON STREET, LONDON X0 W1S 3AN
Steve Myint	director	C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632